泓博医药
(301230)
| 流通市值：18.84亿 | | | 总市值：34.15亿 |
| 流通股本：5937.17万 | | | 总股本：1.08亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 367,212,523.37 | 237,655,059.97 | 121,392,447.24 | 478,883,784.02 |
| 营业收入 | 367,212,523.37 | 237,655,059.97 | 121,392,447.24 | 478,883,784.02 |
| 二、营业总成本 | 319,387,817.06 | 200,328,331.16 | 104,504,260.72 | 409,404,459.84 |
| 营业成本 | 240,119,484.14 | 149,336,941.34 | 77,917,655.65 | 302,301,235.06 |
| 税金及附加 | 915,160.49 | 555,131.18 | 312,473.12 | 1,661,733.28 |
| 销售费用 | 8,888,306.9 | 5,522,548.53 | 2,563,164.87 | 8,118,909.95 |
| 管理费用 | 43,886,738.79 | 28,819,361.45 | 13,311,726.49 | 72,047,018.45 |
| 研发费用 | 28,719,012.45 | 19,284,150.46 | 10,163,571.92 | 32,652,599.49 |
| 财务费用 | -3,140,885.71 | -3,189,801.8 | 235,668.67 | -7,377,036.39 |
| 其中:利息费用 | 2,940,547.93 | 2,030,341.21 | 1,045,393.66 | 4,792,709.47 |
| 其中:利息收入 | 4,163,429.14 | 3,518,749.04 | 3,058,391.18 | 2,883,818.4 |
| 加:公允价值变动收益 | 2,357,183.57 | -2,986,215.19 | 901,397.8 | -99,354.73 |
| 加:投资收益 | 726,006.94 | 3,015,155.93 | 461,082.24 | 603,323.91 |
| 资产处置收益 | 5,799.54 | 3,020.49 | 3,020.49 | - |
| 资产减值损失(新) | -2,407,037.97 | -2,009,778.3 | -1,365,671.84 | -2,163,660.74 |
| 信用减值损失(新) | -151,336.61 | 1,005,917.8 | 66,893.06 | 252,660.06 |
| 其他收益 | 1,139,587.97 | 416,428.87 | 413,168.87 | 4,772,986 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 49,494,909.75 | 36,771,258.41 | 17,368,077.14 | 72,845,278.68 |
| 加:营业外收入 | 6,750.22 | 6,750.02 | 6,150.02 | 205,669.67 |
| 减:营业外支出 | 502,018.64 | 279,580.57 | 137,019.6 | 129,425.36 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 48,999,641.33 | 36,498,427.86 | 17,237,207.56 | 72,921,522.99 |
| 减:所得税费用 | 3,065,623.61 | 3,610,235.1 | 1,961,411.21 | 5,745,640.54 |
| 六、净利润 | 45,934,017.72 | 32,888,192.76 | 15,275,796.35 | 67,175,882.45 |
| 持续经营净利润 | 45,934,017.72 | 32,888,192.76 | 15,275,796.35 | 67,175,882.45 |
| 归属于母公司股东的净利润 | 45,934,017.72 | 32,888,192.76 | 15,275,796.35 | 67,175,882.45 |
| (一)基本每股收益 | 0.43 | 0.31 | 0.2 | 1.1 |
| (二)稀释每股收益 | 0.43 | 0.31 | 0.2 | 1.1 |
| 八、其他综合收益 | 69,910.26 | 82,460.86 | 82,460.86 | -30,320.53 |
| 归属于母公司股东的其他综合收益 | 69,910.26 | 82,460.86 | 82,460.86 | -30,320.53 |
| 九、综合收益总额 | 46,003,927.98 | 32,970,653.62 | 15,358,257.21 | 67,145,561.92 |
| 归属于母公司股东的综合收益总额 | 46,003,927.98 | 32,970,653.62 | 15,358,257.21 | 67,145,561.92 |
| 公告日期 | 2023-10-26 | 2023-08-29 | 2023-04-26 | 2023-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |